While attempting to identify tumours that might benefit from targeted cancer therapies, Weidemann et al. observed that the highest prevalence of MSLN positivity was present in ovarian carcinomas (97% serous), based on analyses of tissue microarrays for MSLN expression in 122 different tumour types. The gene discussed is MSLN; the disease is cancer.